4scar22
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03125577)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4scar22
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04429438 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2020 | Shenzhen Geno-Immune Medical Institute, Shenzhen University, Sun Yat-Sen University |
| NCT03098355 | Phase 1/Phase 2 (Phase 2) | Jul 15, 2017 | Shenzhen Geno-Immune Medical Institute, Southern Medical University |
| NCT03125577 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | Shenzhen Geno-Immune Medical Institute |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 3 | 2 | 1 | 2017 |
| Shenzhen University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Southern Medical University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1